Zavation receives FDA approval for new spinal fusion device — 3 insights

Written by Alan Condon | June 05, 2019 | Print  |

Zavation received 510(k) clearance from the FDA to market its Ti3Z Interbody System for spinal fusions.

Three insights:

1. The Ti3Z Interbody System is to be used at either one or two levels in the lumbar spine.

2. The device is intended to treat degenerative disc disease with up to Grade I spondylolisthesis after patients have had six months of failed non-operative treatment.

3. The titanium implants have an internal porous structure and an external solid surface developed to engage with the vertebral body end plates.

"The interior lattice structure promotes osseointegration and optimal elasticity, while the external edges of the implant maintains mechanical stability," said Jeffrey Johnson, CEO of Zavation.

More articles on surface technology:
Anika to showcase hyaluronic acid-based cartilage repair scaffold
4 key updates in surface technology for spine
Alphatec launches new titanium interbody implant for spine – 3 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months